Work

Clinical advancements of biologic agents in the treatment of Kawasaki disease based on its pathogenesis

Year: 2025

Type: article

Abstract: Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute febrile systemic vasculitis predominantly affecting children under the age of 5 years. The hallmark of KD is systemic vasculitis, which can lead to coronary artery complications if not promptly treated. Approximately 15%–20% of untreated cases develop coronary artery aneurysms, coronary artery stenosis, or thrombosis, posing significant risks to pediatric health and survival. In recent years, the incidence of KD has shown an upward trend. While intravenous immunoglobulin in combination with aspirin remains the standard first-line therapy for acute KD, some patients exhibit resistance to intravenous immunoglobulin or progress to refractory KD. The rapid advancement of modern biomedicine has led to increased interest in biological agents for KD treatment, yielding promising outcomes.

Source: AIMS Allergy and Immunology

DOI: 10.3934/allergy.2025008

Authors: Qi-Ling Yin, You-Qiong Liu, Hui-Min Zhang, Wei-Hua Zhang

Institution: Shaanxi University of Chinese Medicine

Language: English

Topic: Kawasaki Disease and Coronary Complications

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: Natural Science Foundation of Shaanxi Province